Mexico acquires Paxlovid, oral treatment against Covid-19 from Pfizer

The Government of Mexico announced the signing of a purchase agreement for the oral antiviral therapy against him Covid-19 of Pfizer, called Paxlovid.

Said contract contemplates the acquisition of 300 thousand oral treatments which have already begun their arrival in the country.

Pfizer’s antiviral treatment, focused on being administered to people who have the disease caused by the SARS-CoV-2 virus and who are at high risk of developing complications, was approved by the Federal Commission for the Protection against Sanitary Risks (Cofepris) last January 2022, being the first health regulation agency in Latin America to approve it, and the second country in the region to be supplied.

Read also: UNAM researchers redesign Covid tests at low cost and with faster results

The treatment includes nirmatrelvir, a protease inhibitor that was specifically designed to block the activity of SARS-CoV-2 protease 3CL, an enzyme that the coronavirus needs to replicate.

Data show that this treatment reduces the risk of hospitalization or death by 89% when started within three days of symptom onset and by 88% when started within the fourth to fifth day of symptom onset. of symptoms compared to placebo.

Constance Losadapresident and CEO of Pfizer Mexico, said that this agreement helps them continue working hand in hand with the Government of Mexico to address this public health crisis.

Read also: López-Gatell affirms that the Covid-19 pandemic continues with a reduction trend

“The fight and commitment to end the effects of the pandemic is everyone’s task and this is reflected in the agreement we have signed to continue seeking the well-being of people,” he said.

To date, Pfizer has supplied more than 26.2 million oral treatments against Covid-19 to 41 countries.

The drug is designed to block the activity of Mpro, an enzyme that the coronavirus needs to multiply and is unique to coronaviruses and not found in humans.

Read also: These are the vaccination requirements against Covid-19 for 8-year-old children in CDMX

Co-administration with a low dose of ritonavir helps slow down the metabolism or breakdown of nirmatrelvir so that it remains active in the body longer at higher concentrations to help fight the virus.

Pfizer noted that nirmatrelvir showed no evidence of mutagenic interactions with the DNA.

Nirmatrelvir has demonstrated consistent antiviral activity in vitro against former and current variants such as Alpha, Beta, Delta, Gamma, Lambda, Mu and omicron.

How is Paxlovid, the new drug for Covid?

It is a drug produced by the pharmaceutical company Pfizer and recommended by the World Health Organization (WHO) to treat early stages of the Covid-19 disease in patients at risk of hospitalization, such as the elderly, immunosuppressed or unvaccinated.

Read also: Paxlovid: how is the new drug for Covid that Biden takes

Paxlovid actually consists of two drugs, nirmatrelvir and ritonavir. The former is an antiviral and the latter is a pharmacokinetic enhancer.

Paxlovid is only recommended for adults and adolescents 12 years of age and older.

The oral antiretroviral drug from the Pfizer laboratory is administered in the early stages of the disease, when serious symptoms have not yet developed. One tablet is taken orally every 24 hours for five days. According to the WHO, it is indicated for patients “with non-severe forms of Covid-19 who are at high risk of evolving into severe forms of the disease and of being hospitalized, such as unvaccinated, elderly or immunosuppressed patients.”

Rebound effect

One of the biggest questions that experts raised about the drug is the “rebound” effect that was seen in some patients after taking it. Fauci himself experienced this phenomenon, when after three days of negative rapid tests for Covid-19, he contracted the virus again, manifesting some mild symptoms such as low-grade fever, sore throat and body aches.

Read also: What is known about the rebound effect of the drug Paxlovid?

Fauci, however, persisted in his defense of Paxlovid, arguing that the drug served “its original purpose” which was to prevent his hospitalization. “It’s not meant to prevent rebounds. It is meant to prevent you from being hospitalized. I’m 81 years old, I was at risk of hospitalization and I wasn’t even sick enough to be hospitalized,” Fauci told reporters.
With information from La Nación/GDA

subscribe here to receive directly in your email our newsletters on news of the day, opinion, Qatar 2022 and many more options.

aosr/rmlgv

Source link

About John

Check Also

Desperate efforts to save a stray and starving beluga whale in the Seine River

Leo Sands and George Wright BBCNews 4 hours image source, Getty Images Caption, Scientific observers …

Leave a Reply

Your email address will not be published.